Serine

Serine

SCHEMBL4956028

C[C@H](NN1CCCC1)C(=O)O.N[C@@H](CO)C(=O)O

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 1/20 0.40
SLC7A5 Q01650 1/20 0.36
SLC1A1 P43005 4/20 0.34
LTA4H P09960 2/20 0.34
SLC1A3 P43003 4/20 0.33
SLC1A2 P43004 4/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
CHRM1 P11229 1/20 0.31
PTGS1 P23219 1/20 0.31
SLC7A11 Q9UPY5 1/20 0.31
MME P08473 1/20 0.30
GRIK1 P39086 2/20 0.30
GRIA2 P42262 2/20 0.30
GRIA4 P48058 2/20 0.30
GRIK3 Q13003 2/20 0.30
GRIK5 Q16478 2/20 0.30
GRIA1 P42261 1/20 0.30
GRIK2 Q13002 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alanine SCHEMBL4954723 0.84 LTA4H (0.35) DPP7SLC7A5LTA4HL3MBTL1CHRM1
SCHEMBL385711 0.84 L3MBTL1 (0.36) DPP7LTA4HL3MBTL1CHRM1MME
SCHEMBL385712 0.84 L3MBTL1 (0.36) DPP7LTA4HL3MBTL1CHRM1MME
SCHEMBL383047 0.82 L3MBTL1 (0.39) DPP7LTA4HL3MBTL1CHRM1MME
SCHEMBL383046 0.82 L3MBTL1 (0.39) DPP7LTA4HL3MBTL1CHRM1MME
Glycine SCHEMBL4955873 0.81 GLRA1 (0.36) DPP7LTA4HL3MBTL1CHRM1MME
Threonine SCHEMBL4955781 0.79 SLC7A5 (0.36) DPP7SLC7A5LTA4H
SCHEMBL4956023 0.78 DPP7 (0.38) DPP7SLC7A5SLC1A1LTA4HSLC1A3
Pyrrole SCHEMBL28327955 0.74 L3MBTL1 (0.38) L3MBTL1
Serine SCHEMBL28242846 0.72 SLC1A1 (0.52) DPP7SLC7A5SLC1A1SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439226-B2 Serine protease inhibitors THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2008-10-21 US disclosed
WO-2006043933-A1 SERINE PROTEASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-04-27 WO disclosed
US-20050130883-A1 Serine protease inhibitors THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130883-A1 Serine protease inhibitors PRSS1, TASP1, METAP1 DPP7 173/4885SLC7A5 2539/4885SLC1A1 2625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.